Seminars in Oncology
Volume 34 , Pages S8-S12 , December 2007

Pharmacology and Mechanism of Action of Forodesine, a T-Cell Targeted Agent

  • Varsha Gandhi

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Varsha Gandhi, PhD, Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Box 71, Houston, TX 77030
    • Dr Gandhi has received research grant support, honoraria, and consulting fees from BioCryst Pharmaceuticals.
    • ,
  • Kumudha Balakrishnan

References 

  1. Krenitsky TA. Purine nucleoside phosphorylase: Kinetics, mechanism, and specificity. Mol Pharmacol. 1967;3:526–536
  2. Kim BK, Cha S, Parks RE. Purine nucleoside phosphorylase from human erythrocytes (I. Purification and properties). J Biol Chem. 1968;243:1763–1770
  3. Tebbe J, Bzowska A, Wielgus-Kutrowska B, et al. Crystal structure of the purine nucleoside phosphorylase (PNP) from Cellulomonas sp. and its implication for the mechanism of trimeric PNPs. J Mol Biol. 1999;294:1239–1255
  4. Giblett ER, Ammann AJ, Wara DW, et al. Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity. Lancet. 1975;1:1010–1013
  5. Carson DA, Kaye J, Seegmiller JE. Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: Possible role of nucleoside kinase(s). Proc Natl Acad Sci U S A. 1977;74:5677–5681
  6. Martin DW, Gelfand EW. Biochemistry of diseases of immunodevelopment. Annu Rev Biochem. 1981;50:845–877
  7. Carson DA, Kaye J, Matsumoto S, et al. Biochemical basis for the enhanced toxicity of deoxyribonucleosides toward malignant human T cell lines. Proc Natl Acad Sci U S A. 1979;76:2430–2433
  8. Mitchell BS, Mejias E, Dadonna PE, et al. Purinogenic immunodeficiency diseases: Selective toxicity of deoxyribonucleosides for T cells. Proc Natl Acad Sci U S A. 1978;75:5011–5014
  9. Cohen A, Lee JW, Gelfand EW. Selective toxicity of deoxyguanosine and arabinosyl guanine for T-leukemic cells. Blood. 1983;61:660–666
  10. Morris PE, Elliott AJ, Walton SP, et al. Synthesis and biological activity of a novel class of purine nucleoside phosphorylase inhibitors. Nucleosides Nucleotides Nucleic Acids. 2000;19:379–404
  11. dos Santos DM, Canduri F, Pereira JH, et al. Crystal structure of human purine nucleoside phosphorylase complexed with acyclovir. Biochem Biophys Res Commun. 2003;308:553–559
  12. Krenitsky TA, Elion GB, Henderson AM, et al. Inhibition of human purine nucleoside phosphorylase (Studies with intact erythrocytes and the purified enzyme). J Biol Chem. 1968;243:2876–2881
  13. Kazmers IS, Mitchell BS, Dadonna PE, et al. Inhibition of purine nucleoside phosphorylase by 8-aminoguanosine: Selective toxicity for T lymphoblasts. Science. 1981;214:1137–1139
  14. Gilbertsen RB, Josyula U, Sircar JC, et al. Comparative in vitro and in vivo activities of two 9-deazaguanine analog inhibitors of purine nucleoside phosphorylase, CI-972 and PD 141955. Biochem Pharmacol. 1992;44:996–999
  15. Viegas TX, Omura GA, Stoltz RR, et al. Pharmacokinetics and pharmacodynamics of peldesine (BCX-34), a purine nucleoside phosphorylase inhibitor, following single and multiple oral doses in healthy volunteers. J Clin Pharmacol. 2000;40:410–420
  16. Schramm VL. Development of transition state analogues of purine nucleoside phosphorylase as anti-T-cell agents. Biochim Biophys Acta. 2002;1587:107–117
  17. Kicska GA, Long L, Horig H, et al. Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes. Proc Natl Acad Sci U S A. 2001;98:4593–4598
  18. Bantia S, Ananth SL, Parker CD, et al. Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor—BCX-1777. Int Immunopharmacol. 2003;3:879–887
  19. Kilpatrick JM, Morris PE, Serota DG, et al. Intravenous and oral pharmacokinetic study of BCX-1777, a novel purine nucleoside phosphorylase transition-state inhibitor: In vivo effects on blood 2’-deoxyguanosine in primates. Int Immunopharmacol. 2003;3:541–548
  20. Gandhi V, Kilpatrick JM, Plunkett W, et al. A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine). Blood. 2005;106:4253–4260
  21. Jacobbson B, Albertioni F, Erikson S. Deoxynucleoside anabolic enzyme levels in acute myelocytic leukemia and chronic lymphocytic leukemia cells. Cancer Lett. 2001;165:195–200
  22. Parker WB, Secrist JA, Waud WR. Purine nucleoside antimetabolites in development for the treatment of cancer. Curr Opin Invest Drugs. 2004;5:592–596
  23. Gandhi V, Kemena A, Keating MJ, et al. Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy. Leukemia Lymphoma. 1993;10:49–56
  24. Gandhi V, Plunkett W, Weller S, et al. Evaluation of the combination of nelarabine and fludarabine in leukemias: Clinical response, pharmacokinetics and pharmacodynamics in leukemia cells. J Clin Oncol. 2001;19:2142–2152
  25. Albertioni F, Lindemalm S, Reichelova V, et al. Pharmacokinetics of cladribine in plasma and its 5′-monophosphate and 5′-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia. Clin Cancer Res. 1998;4:653–658
  26. Balakrishnan K, Nimmanapalli R, Ravandi F, et al. Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells. Blood. 2006;108:2392–2398

 This work was supported in part by National Institutes of Health grant nos. CA57629 and CA81534.

PII: S0093-7754(07)00222-9

doi: 10.1053/j.seminoncol.2007.11.003

Seminars in Oncology
Volume 34 , Pages S8-S12 , December 2007

Article Tools

* Image Usage & Resolution